Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (OBLN) Stock Overview
Explore Obalon Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
OBLN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Obalon Therapeutics, Inc. (OBLN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.92 and a market capitalization of 5.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Dr. Kelly Huang
2
5421 Avenida Encinas Ste F, Carlsbad, CA
2016